Italian biotech company DiaSorin to offer MeMed’s blood tests in Europe and USA
Haifa-based MeMed develops blood testing technology capable of diagnosing whether an infection is bacterial or viral, based on the presence of specific proteins in the blood
Hagar Ravet | 12:04 08.09.2020
Haifa-based automated medical diagnosis startup MeMed Diagnostics Ltd. announced Tuesday it has signed a strategic partnership with Saluggia, Italy-headquartered biotech company DiaSorin SpA. As part of the agreement, DiaSorin will add MeMed’s blood-testing technology—capable of diagnosing whether an infection is bacterial or viral, based on the presence of specific proteins in the blood—to its offering in Europe and USA. In June, MeMed’s test, which the company claims is more than 90% accurate, received regulatory approval in Israel and Europe. The test is conducted on a blood sample and does not require identifying the source of the infection or the specific infected organ, allowing for quick and accurate diagnosis and treatment.